Erminia Massarelli, MD, PhD
The November 2017 FDA approval of the ALK inhibitor alectinib (Alecensa) for the frontline treatment of patients with ALK-positive non–small cell lung cancer (NSCLC) quickly changed the standard of care. But ongoing research suggests that other ALK inhibitors are also poised to significantly impact this patient population.
-positive NSCLC based on recent regulatory decisions and what additional advancements are expected in the year ahead.
OncLive: Please provide an overview of your presentation on targeted therapies for ALK-positive NSCLC.
: ALK-mutated NSCLC [makes up a small percentage] of all NSCLCs, and they are presented in a very selected group. They are usually associated with a never smoking history and a young patient population, and are generally diagnosed at metastatic stage. The treatment of [patients with] ALK-translocated lung cancer has been completely changed by our ability [to develop] ALK inhibitors.
... to read the full story